Delving into the Latest Updates on Talazoparib Tosylate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

BMN 673, Talazoparib, talazoparib

+ [15]

Target

PARP1 x PARP2

Action

inhibitors

Mechanism

PARP1 inhibitors(Poly (ADP-Ribose) polymerase 1 inhibitors), PARP2 inhibitors(Poly (ADP-Ribose) Polymerase 2 inhibitors)

Therapeutic Areas

NeoplasmsSkin and Musculoskeletal DiseasesUrogenital Diseases+ [6]

Active Indication

BRCA Mutation Castration-Resistant Prostate CancerMetastatic castration-resistant prostate cancerBreast Cancer+ [30]

Inactive Indication

Advanced breast cancerAdvanced Endometrial CarcinomaAdvanced Triple-Negative Breast Carcinoma+ [26]

Originator Organization

BioMarin Pharmaceutical, Inc.

Active Organization

Pfizer Inc.

Zenith Epigenetics Ltd.Pfizer Europe MA EEIG

+ [4]

Inactive Organization

Calithera Biosciences, Inc.MediVation, Inc.

BioMarin Pharmaceutical, Inc.

License Organization

Nektar Therapeutics

Strata Oncology, Inc.

Medivation LLC (California)

+ [4]

Drug Highest PhaseApproved

First Approval Date

United States (16 Oct 2018),

Germline BRCA-mutated, HER2-negative metastatic breast cancer

RegulationPriority Review (United States)

Login to view timeline

Structure/Sequence

Molecular FormulaC26H22F2N6O4S

InChIKeyQUQKKHBYEFLEHK-QNBGGDODSA-N

CAS Registry1373431-65-2

Talzenna will be approved for the treatment of gBRCA advanced breast cancer in Korea. In accordance with the Standards for Re-examination of New Drug, it is required to conduct a PMS. Post marketing surveillance is required to determine any problems or questions associated with Talzenna after marketing in Korea, with regard to the following clauses under conditions of general clinical practice. Therefore, through this study, effectiveness and safety of Talzenna will be observed.

Start Date01 Jun 2027

Sponsor / Collaborator

Pfizer Inc.

NCT06844383

/ RecruitingPhase 2

A Randomized Open-label Phase 2 Study of TALazoparib With or Without ENzaluTamide in Patients With Metastatic Castration-Resistant Prostate Cancer and HRR Mutations After Progression on Abiraterone Acetate

The purpose of this study is to find out whether talazoparib in combination with enzalutamide or talazoparib alone delays cancer progression in people with metastatic castration-resistant prostate cancer (mCRPC) who have homologous recombination repair (HRR) mutations and have previously received abiraterone acetate.

Start Date01 Oct 2025

Sponsor / Collaborator

The Prostate Cancer Clinical Trials Consortium LLC

[+3]

NCT05873192

/ RecruitingPhase 2IIT

Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in de Novo Metastatic to Lymph Nodes Prostate Cancer

To learn about the effectiveness of adding talazoparib to the standard of care treatment combination of androgen ablation therapy (hormone therapy, also known as ADT) and enzalutamide in patients with prostate cancer that has spread into the lymph nodes.

Start Date03 Jun 2025

Sponsor / Collaborator

The University of Texas MD Anderson Cancer Center

100 Clinical Results associated with Talazoparib Tosylate

Login to view more data

100 Translational Medicine associated with Talazoparib Tosylate

Login to view more data

100 Patents (Medical) associated with Talazoparib Tosylate

Login to view more data

802

Literatures (Medical) associated with Talazoparib Tosylate

01 Jan 2026·Genes & Diseases

Targeting fatty acid synthase to overcome PARP inhibitor resistance and to create an artificial synthetic lethality for triple-negative breast cancer

Article

Author: Zhang, Jian-Ting ; Liu, Jing-Yuan ; Josephraj, Sophia ; Cui, Qingbin ; Wang, Chao J ; Dong, Zizheng

Despite advances in cancer treatment with targeted therapies and immunotherapies, triple-negative breast cancer (TNBC) has not significantly benefited from these developments. Although poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) are approved for breast cancer, their clinical use is largely limited to the small subset of HER2-negative patients with germline BRCA1/2 mutations, and resistance is frequently observed. Previously, we demonstrated that proton pump inhibitors (PPIs), including lansoprazole and its metabolite, 5-hydroxy lansoprazole sulfide (5HLS), reduce PARP1 expression by inhibiting fatty acid synthase (FASN), a key enzyme in de-novo lipid synthesis. We also found that PPIs synergize with DNA-damaging agents by regulating PARP1 expression and impairing non-homologous end joining (NHEJ) repair of DNA damage. These findings led to the hypothesis that PPIs synergize with PARPi independently of BRCA mutation, potentially expanding the utility of PARPi to a broader TNBC population. In this study, we show that FASN contributes to PARPi resistance, and that lansoprazole and 5HLS strongly synergize with olaparib and talazoparib in both BRCA1-mutant and wild-type TNBC cells. This synergy occurs through FASN inhibition and subsequent impairment of NHEJ repair of double-strand breaks induced by PARPi trapping. 5HLS also facilitates PARPi-induced PARP1 trapping and inhibits BRCA1 expression by inhibiting FASN, contributing to the synergy with PARPi in both BRCA1 wild-type and mutant TNBC cells. Together, these findings suggest that inhibiting FASN with PPIs creates an artificial synthetic lethality, providing a rationale for combining PPIs with PARPi to expand their utility to TNBC patients without germline BRCA1 mutations and to overcome PARPi resistance.

01 Jan 2026·CURRENT CANCER DRUG TARGETS

Clinical Application of PARP1 Inhibitors and Challenges in Cancer Therapy

Article

Author: Cui, Xuehai ; Chen, Yuekang ; Huang, Xinyu ; Li, Enmin ; Nie, Mingcheng ; Cheng, Yinwei ; Lin, Wan ; Luo, Yunlin ; Xu, Liyan

Among the Poly(ADP-ribose) Polymerase (PARP) family in mammals, PARP1 is the first identified and well-studied member that plays a critical role in DNA damage repair and has been proven to be an effective target for cancer therapy. Here, we have reviewed not only the role of PARP1 in different DNA damage repair pathways, but also the working mechanisms of several PARP inhibitors (PARPi), inhibiting Poly-ADP-ribosylation (PARylation) processing and PAR chains production to trap PARP1 on impaired DNA and inducing Transcription- replication Conflicts (TRCs) by inhibiting the PARP1 activity. This review has systematically summarized the latest clinical application of six authorized PARPi, including olaparib, rucaparib, niraparib, talazoparib, fuzuloparib and pamiparib, in monotherapy and combination therapies with chemotherapy, radiotherapy, and immunotherapy, in different kinds of cancer. Furthermore, probable challenges in PARPi application and drug resistance mechanisms have also been discussed. Despite these challenges, further development of new PARP1 inhibitors appears promising as a valuable approach to cancer treatment.

01 Jan 2026·Therapeutic Advances in Medical Oncology

Efficacy and safety of PARP inhibitors in metastatic breast cancer patients with homologous recombination repair pathway gene mutations: a retrospective multicenter real-world study

Article

Author: Zhang, Jintao ; Xu, Binghe ; Zhang, Pin ; Wang, Jiani ; Luo, Yang ; Fan, Ying ; Peng, Xuenan ; Sun, Xiaoying ; Mo, Hongnan ; Lan, Bo ; Wang, Jiayu ; Chen, Shanshan ; Ma, Fei ; Song, Ruixia ; Li, Qiao

Background::

The efficacy and safety of poly (ADP-ribose) polymerase inhibitors (PARPis) in the Chinese real-world setting have not been well characterized.

Design::

This is a retrospective analysis of PARPis efficacy in metastatic breast cancer (MBC) patients with homologous recombination repair (HRR) gene pathogenic variants (PVs).

Objectives::

We aimed to evaluate the efficacy and toxicities of PARPis in real-world MBC patients.

Methods::

Patients who received PARPi for MBC at the National Cancer Center and two other centers between January 1, 2019, and December 31, 2024, were consecutively included. The primary endpoint was progression-free survival (PFS). Univariable and multivariable Cox proportional hazard models were used to evaluate the predictive impact of clinicopathologic characteristics on PFS.

Results::

In total, 62 MBC patients treated with olaparib ( N = 55), talazoparib ( N = 4), pamiparib ( N = 2), and fluzoparib ( N = 1) were enrolled. The median PFS (mPFS) in all patients was 6.0 months (95% confidence interval: 4.1–7.9). mPFS in the germline BRCA1 (g BRCA1; N = 19), g BRCA2 ( N = 30), g BRCA ( N = 4), somatic BRCA2 (s BRCA2; N = 1), g PALB2 ( N = 4), and other HRR gene ( N = 4) PVs carriers were 3.7, 8.0, 2.8, 2.7, 5.3, and 7.1 months, respectively ( p = 0.334). In multivariate analysis, ⩽40 years old (hazard ratio (HR): 2.281, p = 0.008), third-line or later therapy (HR: 2.429, p = 0.019), and prior platinum-based treatment (HR: 2.172, p = 0.014) were independently associated with shorter PFS. The incidence of adverse events (AEs) of all grades was 62.5% (35/56). The most common AEs in all grades were anemia (30.4%), nausea (21.4%), and leukopenia (17.9%). Hematologic toxicity was the most common grade ⩾3 AEs.

Conclusion::

PARPis showed promising PFS and tolerable toxicity in the real-world treatment of Chinese MBC patients with HRR-related gene mutations.

161

News (Medical) associated with Talazoparib Tosylate

26 Jan 2026

·www.pharmaceutical-technology.com

NICE greenlights Pfizer’s Talzenna for NHS use

The UK health watchdog has changed its stance on Pfizer’s Talzenna, now recommending the once-daily drug for NHS use. Image credit: NMK-Studio via Shutterstock.com. The UK’s National Institute for Health and Care Excellence (NICE) has recommended Pfizer’s Talzenna (talazoparib) in a step forward for patients in England with prostate cancer. Following the NICE’s decision on 23 January, the once-daily pill will be available to patients with metastatic prostate cancer through the National Health Service (NHS) – adding to its previous recommendation for the drug’s use in metastatic breast cancer . NICE is recommending Talzenna’s use when taken alongside hormonal therapy Xtandi (enzalutamide). Talzenna-Xtandi is specifically indicated for patients with prostate cancer who are not eligible to receive treatment with standard of care (SoC) hormonal therapy plus corticosteroid combinations such as abiraterone-prednisolone. This recommendation marks a shift in stance for NICE, which provisionally stated last year it would not support the drug’s use in prostate cancer. However, the UK health watchdog has since reconsidered its position based on the outcome of a public consultation. Talzenna is a poly-ADP ribose polymerase (PARP) inhibitor that acts by blocking the repair of single-strand breaks in cancer cells, causing genomic instability and cancer cell death. According to Helen Knight, director of medicines evaluation at NICE, the Talzenna recommendation is an “important step forward” for patients with prostate cancer – particularly for those who are unable to receive treatment with chemotherapy or other commonly used medicines. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence Knight also touted Talzenna-Xtandi’s at-home administration, which provides a “convenient and flexible” treatment option for patients. The Institute of Cancer Research welcomed the news, stating: “The recommendation marks an important step forward in giving people more treatment options – especially those who cannot undergo chemotherapy. Patients can take the once-daily pill at home, offering convenience and flexibility.” Talzenna is one of three drugs for prostate cancer treatment to recently secure NICE approval, with Bayer and Orion’s oral androgen receptor therapy Nubeqa (darolutamide) and Zytiga (abiraterone) plus its generics being recommended for NHS use in October 2025. The combination therapy first gained US regulatory approval alongside androgen receptor inhibitor Xtandi in prostate cancer in 2023 while the European Commission (EC) approved Talzenna-Xtandi in 2024. Talzenna faces competition in prostate cancer market While the NICE’s decision is a win for Pfizer, Talzenna is part of a competitive metastatic prostate cancer market. This includes AstraZeneca’s PARP inhibitor Lynparza (olaparib), which GlobalData estimates will bring in global sales of $3.5bn at its sales peak across all indications in 2027. However, the drug’s market exclusivity expires in 2027, leaving it vulnerable to generic competition. GSK’s PARP inhibitor Zejula (niraparib) is also a strong market contender, with GlobalData estimating that the drug will generate $791m in global sales at its 2027 peak. Pharma & Schweiz’s Rubraca (rucaparib) also cemented itself in the US market recently, as the PARP inhibitor gained full approval from the US Food and Drug Administration (FDA) in late December 2025. Pharma & Schweiz previously acquired the drug from Clovis Oncology for up to $135m as the latter company looked to sell its assets amid Chapter 11 bankruptcy. GlobalData forecasts that Rubraca will make $139m at its 2029 sales peak in prostate cancer. GlobalData, parent company of Pharmaceutical Technology , forecasts that Talzenna will make global sales of $636m in 2031.

Drug ApprovalAcquisition

26 Jan 2026

·www.icr.ac.uk

ICR welcomes NICE recommendation of talazoparib for advanced prostate cancer

The Institute of Cancer Research, London, welcomes the decision by the National Institute for Health and Care Excellence (NICE) to recommend the targeted drug talazoparib (trade name Talzenna), in combination with enzalutamide, for adults with prostate cancer that has spread. The judgement makes this new drug combination available for around 2,400 patients in England who cannot take standard treatments and for whom chemotherapy is not suitable. The recommendation marks an important step forward in giving people more treatment options – especially those who cannot undergo chemotherapy. The once-daily pill can be taken at home, offering convenience and flexibility for patients. Professor Johann de Bono, Regius Professor of Cancer Research at The Institute of Cancer Research (ICR) and Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust, led the first-in-human talazoparib trial as well as the phase II TALAPRO-1 trial, which showed that talazoparib could kill prostate cancer cells and prevent its growth. The trial demonstrated the effectiveness and tolerability of the drug for the first time in prostate cancer. The follow-up phase III trial, TALAPRO-2, tested the drug in combination with enzalutamide, with results providing the basis for the NICE recommendation. Talazoparib is a PARP inhibitor – it blocks an enzyme that repairs damaged DNA in certain cancer cells. Cancer cells with DNA repair gene faults – such as BRCA, ATM or PALB2 – already have a defective DNA repair system. By using a drug to block PARP, which helps repair DNA when it is damaged, cancer cells are unable to repair themselves. Twenty years ago, a team of ICR researchers first discovered that PARP inhibitors could be used to target BRCA-mutated cancers. Together with The Royal Marsden, researchers at the ICR including Professor Johann de Bono trialled a PARP inhibitor called olaparib in patients with breast and prostate cancer containing DNA repair gene faults. A team of ICR researchers, led by Professor Alan Ashworth and Professor Chris Lord in the Breast Cancer Now Toby Robins Research Centre, first described talazoparib and explained how it works in 2013. Researchers at the ICR then led the first trials of the drug in humans, in 2017. The drug now joins olaparib as one of the first genetically targeted treatments for prostate cancer. As a targeted therapy, it is a much kinder option for patients than chemotherapy. Professor Johann de Bono, Regius Professor of Cancer Research at The Institute of Cancer Research, London, and Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust, said: “There is an urgent need for effective treatment options after hormonal therapies have stopped working against advanced prostate cancer. The approval of talazoparib will provide another treatment option for these men. The pill can be taken at home, and it comes without many of the side effects of chemotherapy. “In our TALAPRO-1 trial, we showed that talazoparib – a type of PARP inhibitor – kills prostate cancer cells and puts this into remission, especially in men whose tumours have faults in DNA repair genes such as BRCA mutations. The follow-up trial, TALAPRO-2, provided the basis of today’s decision.”

Phase 3Clinical ResultPhase 2Drug Approval

23 Jan 2026

·firstwordpharma.com

NICE U-turn allows NHS funding of Pfizer's Talzenna for prostate cancer

Having recently widened access to abiraterone, the National Institute for Health and Care Excellence (NICE) on Friday issued another decision that will benefit prostate cancer patients in the UK, this time backing use of Pfizer's Talzenna (talazoparib) for those with advanced disease. The recommendation comes a matter of months after the cost-effectiveness body also issued a positive assessment of Bayer's Nubeqa (darolutamide).NICE's ruling on Talzenna represents something of a U-turn, having published draft guidance last August against use of the oral PARP inhibitor with Pfizer and Astellas' androgen receptor signalling inhibitor Xtandi (enzalutamide) for untreated hormone-relapsed metastatic prostate cancer in adults when chemotherapy is not clinically indicated. At the time, NICE noted that the available evidence — which included indirect comparisons with standard treatments such as Xtandi alone or abiraterone plus prednisolone — does not suggest that the combination is value for money in this population.However, NICE said Friday that Talzenna is now recommended, alongside Xtandi, for adults with prostate cancer that has spread. Specifically, Pfizer's once-daily drug is recommended for people where chemotherapy is not suitable and who cannot tolerate or take abiraterone plus prednisolone.Study results showed that in people taking Talzenna with Xtandi, overall survival was 45.8 months compared with 37 months for those on Xtandi alone. The time people lived without their cancer getting worse also increased: 33.1 months compared with 19.5 months. Helen Knight, director of medicines evaluation at NICE, said the combination of Talzenna plus Xtandi "can be taken at home, so provides a convenient and flexible treatment option for people who can't have chemotherapy and are not able to take other medicines so have limited treatment options." NICE noted that this will also reduce pressure on the National Health Service (NHS).The cost-effectiveness body indicated that a confidential commercial arrangement is in place to provide Talzenna to the NHS at a discounted price.

Clinical ResultDrug ApprovalPhase 3

100 Deals associated with Talazoparib Tosylate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Talazoparib Tosylate	L01XX60	DB11760

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
BRCA Mutation Castration-Resistant Prostate Cancer	Japan	Pfizer Japan, Inc.	18 Jan 2024
Metastatic castration-resistant prostate cancer	European Union	Pfizer Inc.	08 Jan 2024
Metastatic castration-resistant prostate cancer	Iceland	Pfizer Inc.	08 Jan 2024
Metastatic castration-resistant prostate cancer	Liechtenstein	Pfizer Inc.	08 Jan 2024
Metastatic castration-resistant prostate cancer	Norway	Pfizer Inc.	08 Jan 2024
Breast Cancer	South Korea	Pfizer Inc.	30 Jul 2020
HRR Gene-mutated Castration-Resistant Prostate Cancer	Australia	Pfizer Australia Pty Ltd.	18 Nov 2019
Metastatic breast cancer	Canada	PF Consumer Healthcare Canada ULC	06 Sep 2019
Hormone receptor positive breast cancer	European Union	Pfizer Europe MA EEIG	20 Jun 2019
Hormone receptor positive breast cancer	Iceland	Pfizer Europe MA EEIG	20 Jun 2019
Hormone receptor positive breast cancer	Liechtenstein	Pfizer Europe MA EEIG	20 Jun 2019
Hormone receptor positive breast cancer	Norway	Pfizer Europe MA EEIG	20 Jun 2019
Germline BRCA-mutated, HER2-negative metastatic breast cancer	United States	Pfizer Inc.	16 Oct 2018

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Castration-Resistant Prostatic Cancer	NDA/BLA	United States	Pfizer Inc.	17 Feb 2023
Metastatic Castration-Sensitive Prostate Carcinoma	Phase 3	United States	Pfizer Inc.	12 May 2021
Metastatic Castration-Sensitive Prostate Carcinoma	Phase 3	China	Pfizer Inc.	12 May 2021
Metastatic Castration-Sensitive Prostate Carcinoma	Phase 3	Japan	Pfizer Inc.	12 May 2021
Metastatic Castration-Sensitive Prostate Carcinoma	Phase 3	Argentina	Pfizer Inc.	12 May 2021
Metastatic Castration-Sensitive Prostate Carcinoma	Phase 3	Australia	Pfizer Inc.	12 May 2021
Metastatic Castration-Sensitive Prostate Carcinoma	Phase 3	Belgium	Pfizer Inc.	12 May 2021
Metastatic Castration-Sensitive Prostate Carcinoma	Phase 3	Bulgaria	Pfizer Inc.	12 May 2021
Metastatic Castration-Sensitive Prostate Carcinoma	Phase 3	Canada	Pfizer Inc.	12 May 2021
Metastatic Castration-Sensitive Prostate Carcinoma	Phase 3	Czechia	Pfizer Inc.	12 May 2021

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03901469 (TNBC, CTgov)	Phase 2	Triple Negative Breast Cancer	115	Talazoparib+ZEN003694 (Expansion Cohort A - Combination Treatment in Post-TROP2-ADC Patients)	rncuhnbnvu = qbtdomcmve qyygecphii (etjpuzaivr, kvpwcqrbyi - qyzzhtwsgj) View more	-	07 Oct 2025
				Talazoparib+ZEN003694 (Expansion Cohort C - Combination Treatment in TROP2-ADC-naïve Patients)	jdngssbmks = sncgnqinqq nzjngqswpm (lrnriapjph, lfdcxknmop - ymqhevpzid) View more
NCT04337970 (Phase 1b/2 Study of Talazoparib and Axitinib, Pubmed \| Eur Urol Oncol)	Phase 1/2	Locally Advanced Clear Cell Renal Cell Carcinoma	23	Talazoparib	pessmcwjps(wypjfybmry) = xyaujnuaca sllsavhpfe (wrrvufrtiu, 3.5 - 8.4) View more	Negative	01 Aug 2025
NCT03911973 (Pubmed \| Breast Cancer Res Treat) Manual	Phase 1/2	Advanced Triple-Negative Breast Carcinoma \| BRCA mutation positive Breast Cancer HER2 Negative \| ER Negative \| PR Negative ... View more	-	Gedatolisib + Talazoparib	vzqfdteyca(nrecfdeaeh) = mastuftzyy czunoehaip (gfvjaxihsd ) View more	Negative	05 Jun 2025
NCT04849364 (PERSEVERE, CTgov)	Phase 2	Triple Negative Breast Cancer	52	pembrolizumab+inavolisib+capecitabine (Arm 1c: ctDNA Positive Genomically Directed - PI3K Pathway)	belltgyhns = tumexikbil vlazqgmeus (pskakavxpd, wnrpqustfg - aimtmpvysr) View more	-	31 May 2025
				Pembrolizumab+Capecitabine (Arm 2: ctDNA Positive - Standard of Care)	jjednqeybw = qrwmkuacfj jsgvcclrus (jwintzmiwk, jltmtqiike - ytbctsvldf) View more
NCT04846478 (Phase Ia/Ib study, ASCO2025)	Phase 1	Metastatic castration-resistant prostate cancer EZH2	27	Talazoparib 0.75 mg daily + Tazemetostat 600 mg BID	fozbktazxg(ivzllxsocs) = ndkzrqvhih hxhkstzpss (neuxasnexo ) View more	Positive	30 May 2025
				Talazoparib 0.75 mg daily + Tazemetostat 800 mg BID	pqgpnqdjee(gubirrcycg) = hmszswgbab tnxhdwblkh (mgbopftkph )
NCT03395197 (TALAPRO-2, ASCO2025)	Phase 3	Metastatic castration-resistant prostate cancer	805	Talazoparib + Enzalutamide	zhcycavoej(vmwbchlwsl) = nidrlwgjpm cizcyhwmqc (girhawdelz ) View more	Positive	30 May 2025
				Placebo + Enzalutamide	zhcycavoej(vmwbchlwsl) = etvauxivte cizcyhwmqc (girhawdelz ) View more
NCT03395197 (TALAPRO-2, ASCO2025)	Phase 3	HRR Gene-mutated Castration-Resistant Prostate Cancer	399	Talazoparib + Enzalutamide	tqlopgkrcu(hutjmtzdgm): HR = 0.552 (95% CI, 0.325 - 0.937), P-Value = 0.0255 View more	Positive	30 May 2025
				Placebo + Enzalutamide
PF493 (EHA2025)	Phase 1	Acute Myeloid Leukemia TET2 \| IDH1 \| RUNX1 ... View more	24	Talazoparib	thbaszdhps(urufwqazuj) = Febrile neutropenia and sepsis were the most common serious AEs tgtrxifhjm (ddncjcoszm ) View more	Positive	14 May 2025
TAPUR (AACR 12025 \| AACR 22025)	Phase 2	-	29	Talazoparib 1 mg	akrkrgvyxs(zmcrqraawf) = wckjglsrhw kaibgmewzl (ohnqmaoqfi, 29 - 100) View more	Positive	29 Apr 2025
NCT03395197 (TALAPRO-2, AACR2025)	Phase 3	Metastatic castration-resistant prostate cancer First line TMPRSS2-ERG \| TP53 \| PTEN ... View more	687	Talazoparib + Enzalutamide	cdakwlltpl(dpdkhscpju) = ayspgugajg mepeaeyewr (cdlwmgfehx ) View more	Positive	28 Apr 2025
				Placebo + Enzalutamide	cdakwlltpl(dpdkhscpju) = elocivktus mepeaeyewr (cdlwmgfehx ) View more